Market closedNon-fractional
Merus/MRUS
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Merus
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Ticker
MRUS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Utrecht, Netherlands
Employees
201
Website
www.merus.nl
Merus Metrics
BasicAdvanced
$3.5B
Market cap
-
P/E ratio
-$2.74
EPS
1.10
Beta
-
Dividend rate
Price and volume
Market cap
$3.5B
Beta
1.1
Financial strength
Current ratio
5.227
Quick ratio
5.07
Long term debt to equity
2.82
Total debt to equity
3.299
Management effectiveness
Return on assets (TTM)
-24.89%
Return on equity (TTM)
-52.79%
Valuation
Price to revenue (TTM)
75.54
Price to book
8.95
Price to tangible book (TTM)
8.99
Price to free cash flow (TTM)
-19.27
Growth
Revenue change (TTM)
-11.73%
Earnings per share change (TTM)
-17.72%
3-year revenue growth
6.22%
3-year earnings per share growth
2.50%
What the Analysts think about Merus
Analyst Ratings
Majority rating from 14 analysts.
Merus Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.8M
-12.36%
Net income
-$34M
-42.76%
Profit margin
-441.02%
-34.69%
Merus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.43
-$1.04
-$0.59
-
Expected
-$0.88
-$0.73
-$0.74
-$0.81
-$0.78
Surprise
-24.62%
-41.37%
41.01%
-26.86%
-
Merus News
AllArticlesVideos
![Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting](https://cdn.snapi.dev/images/v1/g/2/press16-2459829.jpg)
Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
GlobeNewsWire·1 month ago
![Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting](https://cdn.snapi.dev/images/v1/f/8/press1-2458137.jpg)
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
GlobeNewsWire·1 month ago
![Merus Announces Pricing of Upsized Public Offering of Common Shares](https://cdn.snapi.dev/images/v1/5/p/press13-2452894.jpg)
Merus Announces Pricing of Upsized Public Offering of Common Shares
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merus stock?
Merus (MRUS) has a market cap of $3.5B as of July 04, 2024.
What is the P/E ratio for Merus stock?
The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of July 04, 2024.
Does Merus stock pay dividends?
No, Merus (MRUS) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Merus dividend payment date?
Merus (MRUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Merus?
Merus (MRUS) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
![Buy or sell Merus stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Merus stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.